背景:在美国,超过265000名妇女感染艾滋病毒,但是有限的研究调查了物理,育龄期感染艾滋病毒妇女的精神和行为健康结果。生育前几年的健康状况,怀孕期间和之后会影响妊娠结局和长期健康。了解育龄期感染艾滋病毒妇女的健康结果具有重大的公共卫生重要性,不管他们是否怀孕。关于怀孕和暴露于HIV/抗逆转录病毒药物(HOPE)的健康结果研究是一项前瞻性观察性队列研究,旨在调查随着年龄增长感染HIV的年轻女性的身心健康结果。包括艾滋病毒的病程,参与护理,生殖健康和选择以及心脏代谢健康。我们描述了HOPE研究设计,以及截至2024年1月1日首批437名参与者的特征。
方法:HOPE研究旨在招募和追踪1630名育龄期感染艾滋病毒的妇女,包括那些围产期获得性艾滋病毒的人,在美国9个州和波多黎各的12个临床站点。HOPE研究影响物理,在整个生殖生命过程中,感染艾滋病毒的妇女的精神和社会福祉以及行为(孕前,怀孕,产后,没有或从未怀孕),由社会生态模型提供信息。主要研究领域包括HIV的临床过程,艾滋病毒和抗逆转录病毒药物与生殖健康的关系,妊娠结局和合并症以及种族主义和社会健康决定因素的影响。HOPE于2022年4月开始注册。
背景:HOPE研究获得了哈佛朗伍德校园机构审查委员会的批准,所有HOPE网站的单一机构审查委员会。结果将通过会议介绍传播,同行评审的期刊和摘要。
BACKGROUND: Over 265 000 women are living with HIV in the USA, but limited research has investigated the physical, mental and behavioural health outcomes among women living with HIV of reproductive age. Health status during the reproductive years before, during and after pregnancy affects pregnancy outcomes and long-term health. Understanding health outcomes among women living with HIV of reproductive age is of substantial public health importance, regardless of whether they experience pregnancy. The Health Outcomes around Pregnancy and Exposure to HIV/Antiretrovirals (HOPE)
study is a prospective observational cohort
study designed to investigate physical and mental health outcomes of young women living with HIV as they age, including HIV disease course, engagement in care, reproductive health and choices and cardiometabolic health. We describe the HOPE
study design, and characteristics of the first 437 participants enrolled as of 1 January 2024.
METHODS: The HOPE
study seeks to enrol and follow 1630 women living with HIV of reproductive age, including those with perinatally-acquired HIV, at 12 clinical sites across 9 US states and Puerto Rico. HOPE studies multilevel dynamic determinants influencing physical, mental and social well-being and behaviours of women living with HIV across the reproductive life course (preconception, pregnancy, post partum, not or never-pregnant), informed by the socioecological model. Key research areas include the clinical course of HIV, relationship of HIV and antiretroviral medications to reproductive health, pregnancy outcomes and comorbidities and the influence of racism and social determinants of health. HOPE began enrolling in April 2022.
BACKGROUND: The HOPE
study received approval from the Harvard Longwood Campus Institutional Review Board, the single institutional review board of record for all HOPE sites. Results will be disseminated through conference presentations, peer-reviewed journals and lay summaries.